SK452490A3 - Erection-inducing methods and compositions - Google Patents

Erection-inducing methods and compositions Download PDF

Info

Publication number
SK452490A3
SK452490A3 SK4524-90A SK452490A SK452490A3 SK 452490 A3 SK452490 A3 SK 452490A3 SK 452490 A SK452490 A SK 452490A SK 452490 A3 SK452490 A3 SK 452490A3
Authority
SK
Slovakia
Prior art keywords
impotence
erection
phentolamine
men
vip
Prior art date
Application number
SK4524-90A
Other languages
English (en)
Slovak (sk)
Other versions
SK279489B6 (sk
Inventor
Thomas Gerstenberg
Jan Fahrenkrug
Bent Ottesen
Original Assignee
Senetek Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senetek Plc filed Critical Senetek Plc
Publication of SK279489B6 publication Critical patent/SK279489B6/sk
Publication of SK452490A3 publication Critical patent/SK452490A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Load-Engaging Elements For Cranes (AREA)
  • Cosmetics (AREA)
  • Revetment (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Detergent Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
SK4524-90A 1989-09-18 1990-09-17 Erection-inducing methods and compositions SK452490A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/408,754 US5236904A (en) 1989-09-18 1989-09-18 Erection-inducing methods and compositions

Publications (2)

Publication Number Publication Date
SK279489B6 SK279489B6 (sk) 1998-12-02
SK452490A3 true SK452490A3 (en) 1998-12-02

Family

ID=23617626

Family Applications (1)

Application Number Title Priority Date Filing Date
SK4524-90A SK452490A3 (en) 1989-09-18 1990-09-17 Erection-inducing methods and compositions

Country Status (23)

Country Link
US (1) US5236904A (ro)
EP (1) EP0493485B1 (ro)
JP (1) JP3149946B2 (ro)
KR (1) KR100230720B1 (ro)
AT (1) ATE210994T1 (ro)
AU (1) AU641184B2 (ro)
BR (1) BR9007662A (ro)
CA (1) CA2065270C (ro)
CZ (1) CZ280446B6 (ro)
DE (1) DE69033881T2 (ro)
DK (1) DK0493485T3 (ro)
ES (1) ES2170050T3 (ro)
FI (1) FI104231B (ro)
GE (1) GEP19981264B (ro)
HU (1) HU208088B (ro)
IL (1) IL95505A (ro)
LT (1) LT3544B (ro)
LV (1) LV10198B (ro)
NO (1) NO307498B1 (ro)
RO (1) RO116346B1 (ro)
RU (1) RU2098120C1 (ro)
SK (1) SK452490A3 (ro)
WO (1) WO1991004039A1 (ro)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447912A (en) * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment
US5583144A (en) * 1995-02-24 1996-12-10 Kral; John G. Methods for treating erectile impotence
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US6323211B1 (en) 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US20030004170A1 (en) * 1997-05-19 2003-01-02 Zonagen, Inc. Combination therapy for modulating the human sexual response
US5947901A (en) * 1997-09-09 1999-09-07 Redano; Richard T. Method for hemodynamic stimulation and monitoring
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6482426B1 (en) * 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
US6706682B2 (en) * 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6211156B1 (en) * 1999-11-10 2001-04-03 Asta Medica A.G. Peptides for treatment of erectile dysfunction
US6650943B1 (en) 2000-04-07 2003-11-18 Advanced Bionics Corporation Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction
EP1280531B1 (en) * 2000-05-12 2007-01-24 Novalar Pharmaceuticals, Inc. Formulation consisting of phentolamine mesylate and the use thereof
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
US6885895B1 (en) * 2001-04-26 2005-04-26 Advanced Bionics Corporation Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction
ES2363738T3 (es) * 2005-03-07 2011-08-12 Mondobiotech Ag Formulación de aviptadil.
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
CN102131516B (zh) 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
US9029505B2 (en) * 2009-08-14 2015-05-12 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
US9913748B2 (en) 2009-10-30 2018-03-13 Avner Spector Method and apparatus for treatment of erectile dysfunction with extracorporeal shockwaves
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
GB201221032D0 (en) * 2012-11-22 2013-01-09 Mens Health Ltd Method of treatment
GB201221046D0 (en) * 2012-11-22 2013-01-09 Mens Health Ltd Method of diagnosis
US11052132B2 (en) 2014-05-08 2021-07-06 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
CN114652817B (zh) 2015-02-09 2026-04-17 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物
WO2019102310A1 (en) 2017-11-24 2019-05-31 Alaval (Pty) Ltd Vip formulation for management of inflammatory conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3898329A (en) * 1971-09-17 1975-08-05 Sami I Said Vasoactive intestinal peptide, composition and method
DE3637157A1 (de) * 1985-11-01 1987-05-21 Byk Gulden Lomberg Chem Fab Arzneimittel zur behandlung erektiler dysfunktionen
JPS62246595A (ja) * 1986-04-17 1987-10-27 Eisai Co Ltd 気菅支拡張作用・降圧作用ペプタイド
US4939224A (en) * 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra

Also Published As

Publication number Publication date
DK0493485T3 (da) 2002-03-18
BR9007662A (pt) 1992-07-21
RU2098120C1 (ru) 1997-12-10
IL95505A (en) 1997-03-18
LV10198A (lv) 1994-10-20
NO920915D0 (no) 1992-03-09
DE69033881D1 (de) 2002-01-31
FI104231B1 (fi) 1999-12-15
FI104231B (fi) 1999-12-15
EP0493485A1 (en) 1992-07-08
US5236904A (en) 1993-08-17
HUT60633A (en) 1992-10-28
AU6440490A (en) 1991-04-18
LV10198B (en) 1995-08-20
KR100230720B1 (en) 1999-11-15
EP0493485B1 (en) 2001-12-19
HK1011292A1 (en) 1999-07-09
LTIP1579A (en) 1995-06-26
LT3544B (en) 1995-11-27
NO920915L (no) 1992-03-09
EP0493485A4 (en) 1993-08-18
SK279489B6 (sk) 1998-12-02
CA2065270C (en) 2003-01-14
JPH05500513A (ja) 1993-02-04
HU9200874D0 (en) 1992-05-28
CZ452490A3 (en) 1995-09-13
JP3149946B2 (ja) 2001-03-26
FI921136A0 (fi) 1992-03-17
FI921136A7 (fi) 1992-03-17
WO1991004039A1 (en) 1991-04-04
ATE210994T1 (de) 2002-01-15
DE69033881T2 (de) 2002-09-12
ES2170050T3 (es) 2002-08-01
HU208088B (en) 1993-08-30
RO116346B1 (ro) 2001-01-30
GEP19981264B (en) 1998-07-07
NO307498B1 (no) 2000-04-17
CZ280446B6 (cs) 1996-01-17
CA2065270A1 (en) 1991-03-19
AU641184B2 (en) 1993-09-16

Similar Documents

Publication Publication Date Title
SK452490A3 (en) Erection-inducing methods and compositions
US5447912A (en) Erection-inducing methods and compositions
JP3310982B2 (ja) 男性の勃起機能不全を改善するための剤形及び方法
Gerstenberg et al. Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure
KR19980703052A (ko) 발기 기능장애의 예방 방법 및 키트
JPH04504856A (ja) 勃起障害治療のための医薬組成物および勃起障害の治療方法
JP2003521462A (ja) 男性における器質性勃起機能不全治療のための医薬品製造におけるアポモルヒネの使用
US6187790B1 (en) Use of cilostazol for treatment of sexual dysfunction
Meyhoff et al. Non‐invasive management of impotence with transcutaneous nitroglycerin
US6258373B1 (en) Treatment of sexual dysfunction in certain patient groups
Keogh et al. Treatment of impotence by intrapenile injections. A comparison of papaverine versus papaverine and phentolamine: a double-blind, crossover trial
JP2820737B2 (ja) 男性不能症の治療用物質
Earle et al. The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury
US6110489A (en) Use of quinolines and quinolones to treat male erectile dysfunction
JPH07506333A (ja) 勃起機能不全症治療用ピリジルグアニジン化合物
US6132753A (en) Treatment of sexual dysfunction in certain patient groups
US6303135B1 (en) Use of quinolines and quinolones to treat male erectile dysfunction
WO2002019997A1 (en) Pde iii inhibitors for treating sexual dysfunction
Virag et al. Late results on the treatment of neurogenic impotence by self-intracavernous-injection (SICI) of vasoactive drugs
HK1011292B (en) Erection-inducing methods and compositions
US6426084B1 (en) Treatment of sexual dysfunction in certain patient groups
CN113365620A (zh) 用于治疗耻骨联合松解症的组合物
Mouritsen et al. The intracavernous injection of papaverine as a diagnostic procedure in patients with erectile dysfunction

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20100917